Meredith Kaya | VP, Investor Relations and Corporate Communications |
Peter Hecht | Chief Executive Officer |
Mark Mallon | Executive Senior Advisor |
Thomas McCourt | SVP, Marketing & Sales and Chief Commercial Officer |
Christopher Wright | Chief Development Officer & SVP of Global Development |
Gina Consylman | SVP and Chief Financial Officer |
Mike Shetzline | Chief Medical Officer, SVP and Head of Drug Development |
David Lebowitz | Morgan Stanley |
Jason Zemansky | Barclays |
Boris Peaker | Cowen & Company |
Umer Raffat | Evercore ISI |
Ying Huang | Bank of America Merrill Lynch |
Eric Joseph | J.P. Morgan |
Edward Marks | H.C. Wainwright |
Patrick Trucchio | Berenberg Capital Markets |
Timothy Chiang | BTIG |
Irina Koffler | Mizuho Securities |
Good morning. My name is Emily and I will be your conference operator today. At this time, I would like to welcome everyone to the Ironwood Pharmaceuticals Fourth Quarter and Full-Year 2018 Investor Update. [Operator Instructions] Thank you. Meredith Kaya, you may begin your conference.